Baillie Gifford & Co. Sells 1,771 Shares of Axon Enterprise, Inc $AXON

Baillie Gifford & Co. decreased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 1.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 126,479 shares of the biotechnology company’s stock after selling 1,771 shares during the quarter. Baillie Gifford & Co.’s holdings in Axon Enterprise were worth $90,766,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of AXON. Stone House Investment Management LLC bought a new stake in shares of Axon Enterprise in the third quarter worth approximately $29,000. Hemington Wealth Management boosted its holdings in Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 17 shares during the last quarter. Whipplewood Advisors LLC grew its position in Axon Enterprise by 192.9% in the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 27 shares during the period. Darwin Wealth Management LLC purchased a new stake in Axon Enterprise during the 2nd quarter valued at $37,000. Finally, Root Financial Partners LLC bought a new position in shares of Axon Enterprise during the 3rd quarter valued at $34,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Up 1.0%

AXON stock opened at $613.14 on Friday. The business’s 50-day moving average price is $576.17 and its 200-day moving average price is $676.14. The stock has a market cap of $48.38 billion, a P/E ratio of 194.03, a PEG ratio of 19.30 and a beta of 1.41. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57. Axon Enterprise, Inc has a twelve month low of $469.24 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. During the same quarter in the previous year, the business posted $1.45 EPS. Axon Enterprise’s revenue was up 30.6% on a year-over-year basis. On average, equities research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Activity

In other Axon Enterprise news, CFO Brittany Bagley sold 2,000 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the sale, the chief financial officer owned 103,501 shares in the company, valued at approximately $60,030,580. This represents a 1.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $619.01, for a total value of $6,190,100.00. Following the completion of the transaction, the chief executive officer owned 3,100,997 shares in the company, valued at $1,919,548,152.97. The trade was a 0.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 60,540 shares of company stock worth $34,684,738. 4.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. Piper Sandler reduced their price objective on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Morgan Stanley reduced their price target on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Wall Street Zen cut shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday, December 29th. Finally, Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a report on Tuesday, January 6th. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $805.71.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.